Amicus Q4 revenue beats estimates

Amicus Therapeutics

20/02/2026 21:10

Overview

Biotechnology firm's Q4 revenue rose 24%, beating analyst expectations

Adjusted EPS for Q4 beat analyst expectations

Outlook

Company will not provide financial guidance for 2026 due to pending acquisition

Result Drivers

GALAFOLD SALES - Driven by commercial execution, new patient starts, and strong compliance

POMBILITI + OPFOLDA SALES - High demand from established and new markets drove growth

CASH POSITION - Increased by $44M, reflecting operational growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$185.20 mln
$180.69 mln (9 Analysts)
Q4 Adjusted EPS
Beat
$0.10
$0.09 (8 Analysts)
Q4 EPS
$0.01
Q4 Net Income
$1.70 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Amicus Therapeutics Inc is $14.50, about 1% above its February 19 closing price of $14.35

The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 40 three months ago

Press Release: ID:nGNX8znCKR

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)